Newsmeme!
Discover News you didn't know existed
Pharmacokinetics
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Maas Biolab enters Phase II for development of ALS drug
Published December 5, 2008, 2:50 am, Pharmaceutical Business Review
Maas Biolab, a private pharmaceutical company, has advanced to Phase II of its $2.1 million three-year small business innovation research grant from the National Institute of Neurological Disorders and Stroke for the treatment of amyotrophic lateral sclerosis.
Alkermes Initiates Clinical Trial for ALKS 33, a Novel Oral Molecule with Potential Benefits in Addiction and Other ...
Published December 4, 2008, 5:47 am, Centre Daily Times
Alkermes, Inc. (NASDAQ: ALKS) today announced the initiation of a phase 1 study of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other central nervous system (CNS) disorders. ALKS 33 is the company’s first novel, small molecule drug candidate to enter the clinic. The molecule builds on Alkermes’ scientific expertise in brain reward pathways as well as the ...
Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference
Published December 4, 2008, 5:33 am, Centre Daily Times
Ambit Biosciences today announced that data for the company’s lead compound, AC220, will be presented at the 50 th Annual Meeting of the American Society of Hematology (ASH), occurring December 6 through 9, 2008 in San Francisco. Two oral presentations and one poster presentation will highlight clinical and preclinical data for AC220, a compound that potently and selectively inhibits the ...
Alkermes Initiates Clinical Trial for ALKS 33, a Novel Oral Molecule with Potential Benefits in Addiction and Other ...
Published December 4, 2008, 5:30 am, Business Wire via Yahoo! Finance
CAMBRIDGE, Mass.----Alkermes, Inc. today announced the initiation of a phase 1 study of ALKS 33, an oral opioid modulator for the potential treatment of addiction and other central nervous system disorders.
Ambit Biosciences to Unveil Clinical Data from its AC220 AML Trial at American Society for Hematology Annual Conference
Published December 4, 2008, 5:00 am, Business Wire via Yahoo! Finance
SAN DIEGO----Ambit Biosciences today announced that data for the company’s lead compound, AC220, will be presented at the 50th Annual Meeting of the American Society of Hematology , occurring December 6 through 9, 2008 in San Francisco.
Lexicon Files Investigational New Drug Application For LX4211 As A Potential Treatment For Diabetes
Published December 3, 2008, 11:04 pm, DrugDiscoveryOnline
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company focused on discovering and developing breakthrough treatments for human disease, announced recently that it has submitted an investigational new drug (IND) application to the U.S. Food and Drug Administration (FDA) for LX4211, an oral small molecule drug candidate for type 2 diabetes
YOU ARE HERE:
Published December 3, 2008, 5:00 pm, Aidsmap
A small Ugandan study has shown that 1200mg of fluconazole per day appears to be a better treatment for cryptococcal meningitis than 400 to 800mg per day, which is the dosage typically administered to patients in many African health facilities.
PharmaEngine Receives Approval Of US IND Application For A Phase II Study Of PEP02 (Liposome Irinotecan Injection) In ...
Published December 3, 2008, 12:11 pm, Medical News Today
PharmaEngine, Inc. announced today that it has received approval of an Investigational New Drug (IND) application from the U.S. FDA for PEP02, a liposome formulation of irinotecan in a phase II study in patients with metastatic pancreatic cancer.
Maas Biolab SBIR Enters Phase 2 for Cyclosporin ALS Treatment
Published December 3, 2008, 10:32 am, Centre Daily Times
Maas Biolab has advanced to Phase 2 of its Small Business Innovation Research (SBIR) grant “Intrathecal Cyclosporin for the Treatment of Amyotrophic Lateral Sclerosis (ALS).” Jenny Karlsson, Ph.D., is Maas Director of Preclinical Development and Principal Investigator of the $2.1 million three-year grant from the National Institute of Neurological Disorders and Stroke (NINDS). After successful ...
Maas Biolab SBIR Enters Phase 2 for Cyclosporin ALS Treatment
Published December 3, 2008, 10:20 am, Business Wire via Yahoo! Finance
ALBUQUERQUE, N.M.----Maas Biolab has advanced to Phase 2 of its Small Business Innovation Research grant “Intrathecal Cyclosporin for the Treatment of Amyotrophic Lateral Sclerosis .” Jenny Karlsson, Ph.D., is Maas Director of Preclinical Development and Principal Investigator of the $2.1 million three-year grant from the National Institute of Neurological Disorders and Stroke .
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |